# US 2019/0167608 A1 · Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167608 A1
- Document ID: US20190167608A1
- Status: Published application
- Kind: A1
- Application number: 16/149,892
- Filed: 2018-10-02
- Published: 2019-06-06
- Earliest claimed: 2017-10-02
- Assignees: Texas Woman's University
- Applicants: Texas Woman's University
- Inventors: Michael Bergel; James E. Johnson; Debra Dolliver; Sudheer Dhanireddy; Amon Gekombe
- Web page: https://patentgrep.com/patent/US20190167608A1

## CPC

- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein is the use of bisamidoximes compounds for the treatment of cancer. In preferred embodiments, combinations of two or more bisamidoximes or combinations of a bisamidoxime and another anti-cancer agent were found to be effective against various types of cancer cells.

## Claims

### Claim 1

A method of treating cancer in a subject comprising administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition comprising one or more bisamidoximes.

### Claim 2 (depends on 1)

The method of claim 1, wherein one or more of the bisamidoximes have the structure:
where W: is —(CH2)2—; —(CH2)3—; (CH2)4—; or —(CH2)3—N(CH3)—(CH2)3—; and
where Y is H, C1-C6 alkyl, or halogen.

### Claim 3 (depends on 2)

The method of claim 2, wherein one or more of the bisamidoximes have the structure where Y is methyl.

### Claim 4 (depends on 1)

The method of claim 1, wherein one or more of the bisamidoximes are selected from the group of compounds consisting of JJMB 5, JJMB 7, and JJMB 9:

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises two or more bisamidoximes.

### Claim 6 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition comprises JJMB5 and JJMB 9.

### Claim 7 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition comprises JJMB5 and JJMB7.

### Claim 8 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition comprises JJMB7 and JJMB9.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is lung cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer is colon cancer.

### Claim 12

A method of treating cancer in a subject comprising administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition comprising an anticancer agent and one or more bisamidoximes.

### Claim 13 (depends on 11)

The method of claim 11, wherein the anticancer agent is cisplatin.

### Claim 14 (depends on 11)

The method of claim 11, wherein the one or more bisamidoximes have the structure:
where W: is —(CH2)2—; —(CH2)3—; —(CH2)4—; or —(CH2)3—N(CH3)—(CH2)3—; and
where Y is H, C1-C6 alkyl, or halogen.

### Claim 15 (depends on 13)

The method of claim 13, wherein the one or more bisamidoximes have the structure where Y is methyl.

### Claim 16 (depends on 11)

The method of claim 11, wherein the one or more bisamidoximes are selected from the group of compounds consisting of JJMB 5, JJMB6, JJMB 7, and JJMB 9:

### Claim 17 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition comprises JJMB5.

### Claim 18 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition comprises JJMB7.

### Claim 19 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition comprises JJMB9.

### Claim at position 20

20-23. (canceled)
